FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Sathyanarayanan Sriram		 2. Issuer Name and Ticker or Trading Symbol

Codiak BioSciences, Inc. [ CDAK ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Scientific Officer
(Last)          (First)          (Middle)

C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500		 3. Date of Earliest Transaction (MM/DD/YYYY)

8/16/2022
(Street)

CAMBRIDGE, MA 02140
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 8/16/2022  M  7350 A (1)9102 D  
Common Stock 8/17/2022  S(2)  2283 D$2.2123 6819 D  
Common Stock 2/16/2023  M  7350 A (1)14169 D  
Common Stock 2/17/2023  S(2)  2407 D$0.5922 11762 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units  (3)8/16/2022  M     7350   (4) (4)Common Stock 7350 $0.00 22050 D  
Restricted Stock Units  (3)2/16/2023  M     7350   (4) (4)Common Stock 7350 $0.00 14700 D  
Explanation of Responses:
(1) Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
(2) The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement.
(3) Each RSU represents a contingent right to receive one share of common stock.
(4) On February 16, 2022, the reporting person was granted 29,400 RSUs, vesting in four equal installments every six months beginning on the six months anniversary of the grant date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Sathyanarayanan Sriram
C/O CODIAK BIOSCIENCES, INC.
35 CAMBRIDGEPARK DRIVE, SUITE 500
CAMBRIDGE, MA 02140

Chief Scientific Officer
Signatures
/s/ Yalonda Howze, Attorney-in-Fact for Sriram Sathyanarayanan2/21/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Codiak BioSciences (NASDAQ:CDAK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Codiak BioSciences Charts.
Codiak BioSciences (NASDAQ:CDAK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Codiak BioSciences Charts.